Physician profile
Samuel M Silver
NPI 1457437329
$23,127.68
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,511 · 2021: $2,563 · 2022: $10K · 2023: $1,714 · 2024: $4,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,728 · Travel and Lodging: $697 · Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,727.50 |
| Travel and Lodging | $697.20 |
| Food and Beverage | $164.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $5,962.50 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $4,875.00 | 2024 | Panhematin |
| Mitsubishi Tanabe Pharma Development America, INC. | $4,496.25 | 2022 | |
| Alnylam Pharmaceuticals INC. | $3,557.77 | 2019-2023 | Givlaari |
| Incyte Corporation | $2,018.70 | 2022-2023 | Monjuvi |
| Impedimed, INC. | $1,250.00 | 2021 | |
| Gt Medical Technologies, INC | $612.50 | 2023 | Gammatile |
| Morphosys, US INC. | $240.00 | 2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $64.96 | 2019 | |
| Genzyme Corporation | $50.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.